Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2025-12-25 @ 9:44 PM
Study NCT ID:
NCT04876651
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2021-05-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Sponsor:
Telix Pharmaceuticals (Innovations) Pty Ltd
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-08-29
Start Date Type:
ACTUAL
Primary Completion Date:
2025-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-05-03
First Submit QC Date:
None
Study First Post Date:
2021-05-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-28
Last Update Post Date:
2024-05-31
Last Update Post Date Type:
ACTUAL